Results 181 to 190 of about 5,953 (226)

Hepatitis C: current treatments, emerging therapies and tackling health inequities on the path to global elimination. [PDF]

Clin Med (Lond)
Farooq HZ, Foster GR.
europepmc   +1 more source

From the Editor's desk...: July 2016 [PDF]

, 2016
Bataller, R, Berg, T, Jalan, R, Moreau, R, Zucman-Rossi, J   +4 more
core  

Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials

, 2017
Ira M. Jacobson, Eric Lawitz, Edward Gane, Bernard E Willems, Peter Ruane, Ronald Nahass, Sergio Borgia, Stephen D. Shafran, Kimberly Workowski, Brian L. Pearlman, Robert H. Hyland, Luisa M. Stamm, Evguenia S. Svarovskaia, Hadas Dvory‐Sobol, Yanni Zhu, G. Mani Subramanian, Diana M. Brainard, John G. McHutchison, Norbert Bräu, Thomas Berg, Kosh Agarwal, Bal Raj Bhandari, Mitchell Davis, Jordan J. Feld, Gregory J. Dore, Catherine Stedman, Alexander Thompson, Tarik Asselah, Stuart K. Roberts, Graham R. Foster   +29 more
openalex   +2 more sources

Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. [PDF]

Clin Infect Dis
Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL.   +15 more
europepmc   +1 more source

A case report of sofosbuvir induced drug eruption and literature review. [PDF]

IDCases
Xia A, Liu J, Tang C, Xu H.
europepmc   +1 more source

Evaluation of Treatment Response in Chronic Hepatitis C Patients Receiving Sofosbuvir/Velpatasvir/Voxilaprevir: A Multicenter Real-World Experience from Türkiye. [PDF]

Viruses
Binay UD, Karakeçili F, Aygen B, Kılınç Toker A, Çelik İ, Demirtürk N, Şimşek Bozok T, Dursun L, Akgül F, Çınar G, Günal Ö, Asan A, Arslan E, Yılmaz Karadağ F, Barkay O, Akdemir İ, Şimşek F, Türkoğlu Yılmaz E, Eğilmez ZR, Tekin S, The Viral Hepatitis Study Group Of The Turkish Society Of Clinical Microbiology And Infectious Diseases Klimik.   +20 more
europepmc   +1 more source

Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries. [PDF]

BMJ Open Gastroenterol
Mustafa A, Davlidova S, Abidi SH, Begimbetova D, Heimer R, Vermund SH, Ali S.   +6 more
europepmc   +1 more source

Characteristics of a Chinese Cohort of Patients with Chronic Hepatitis C Infection (2019-2023) and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir Treatment. [PDF]

J Clin Transl Hepatol
Xiong H, Pan S, Zhou C, Shi H, Xie Y, Guo J.   +5 more
europepmc   +1 more source

Epidemiologic Characteristics Determining the Choice of Direct-Acting Antiviral Therapy in HCV Patients: An Italian Real-World Evidence Study. [PDF]

Pathogens
Pugliese N, Conti F, Rosato V, Gallo P, Gitto S, Riglietta M, Frigerio F, Perrone V, Veronesi C, Cappuccilli M, Degli Esposti L, Mangia A, Kondili LA.   +12 more
europepmc   +1 more source

Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis. [PDF]

BMJ Public Health
Nisingizwe MP, Tadrous M, Janjua NZ, Bansback N, Hedt-Gauthier B, Suda KJ, Law MR.   +6 more
europepmc   +1 more source